Form 8-K - Current report:
SEC Accession No. 0001193125-24-003866
Filing Date
2024-01-08
Accepted
2024-01-08 07:07:54
Documents
14
Period of Report
2024-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d87492d8k.htm   iXBRL 8-K 24872
2 EX-99.1 d87492dex991.htm EX-99.1 35480
6 GRAPHIC g87492g0105181214025.jpg GRAPHIC 3504
  Complete submission text file 0001193125-24-003866.txt   197906

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tvtx-20240108.xsd EX-101.SCH 2849
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvtx-20240108_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvtx-20240108_pre.xml EX-101.PRE 11260
8 EXTRACTED XBRL INSTANCE DOCUMENT d87492d8k_htm.xml XML 3362
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 24518303
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)